Pilot Takes Off For Inspecting API Manufacturers By U.S., Europe, Australia
This article was originally published in The Tan Sheet
Executive Summary
FDA and its counterparts in the European Union and Australia have divided responsibilities for inspecting specific active pharmaceutical ingredient facilities in third-country locations in the next 18 months as part of a pilot to monitor more sites